pamidronate has been researched along with Adverse Drug Event in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate patient-reported effectiveness, safety and social influence of Pamidronate in the therapy of NSAIDs-refractory Chronic Recurrent Multifocal Osteomyelitis in children." | 8.12 | Patient-reported effectiveness and safety of Pamidronate in NSAIDs-refractory chronic recurrent multifocal osteomyelitis in children. ( Juszczak, B; Sułko, J, 2022) |
| "Atrial fibrillation (AF) may be triggered by intravenous bisphosphonates (IVBPs) such as zoledronic acid or pamidronic acid." | 5.12 | Atrial fibrillation in patients treated with intravenous zoledronic or pamidronic acid: a pharmacoepidemiological study. ( Arnaud, L; Javier, RM; Lebrun-Vignes, B; Pijnenburg, L; Salem, JE; Sibilia, J, 2021) |
| "To evaluate patient-reported effectiveness, safety and social influence of Pamidronate in the therapy of NSAIDs-refractory Chronic Recurrent Multifocal Osteomyelitis in children." | 4.12 | Patient-reported effectiveness and safety of Pamidronate in NSAIDs-refractory chronic recurrent multifocal osteomyelitis in children. ( Juszczak, B; Sułko, J, 2022) |
| "Osteonecrosis of the jaw is an adverse outcome associated with bisphosphonate treatment." | 3.79 | Sarcoglycans and integrins in bisphosphonate treatment: immunohistochemical and scanning electron microscopy study. ( Catalfamo, L; Centofanti, A; Cutroneo, G; De Ponte, FS; Favaloro, A; Runci, M; Siniscalchi, EN, 2013) |
| "Several studies have suggested that Langerhans cell histiocytosis (LCH) is responsive to treatment with bisphosphonates (BPs)." | 1.37 | Nationwide survey of bisphosphonate therapy for children with reactivated Langerhans cell histiocytosis in Japan. ( Anan, T; Hama, A; Imamura, T; Kamizono, J; Kanegane, H; Kinoshita, A; Kudo, K; Miyaji, R; Morimoto, A; Nagatoshi, Y; Nakadate, H; Nakagawa, S; Sato, T; Shioda, Y; Tauchi, H; Yabe, M; Yasui, M, 2011) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Pijnenburg, L | 1 |
| Salem, JE | 1 |
| Lebrun-Vignes, B | 1 |
| Sibilia, J | 1 |
| Javier, RM | 1 |
| Arnaud, L | 1 |
| Juszczak, B | 1 |
| Sułko, J | 1 |
| De Ponte, FS | 1 |
| Favaloro, A | 1 |
| Siniscalchi, EN | 1 |
| Centofanti, A | 1 |
| Runci, M | 1 |
| Cutroneo, G | 1 |
| Catalfamo, L | 1 |
| Morimoto, A | 1 |
| Shioda, Y | 1 |
| Imamura, T | 1 |
| Kanegane, H | 1 |
| Sato, T | 1 |
| Kudo, K | 1 |
| Nakagawa, S | 1 |
| Nakadate, H | 1 |
| Tauchi, H | 1 |
| Hama, A | 1 |
| Yasui, M | 1 |
| Nagatoshi, Y | 1 |
| Kinoshita, A | 1 |
| Miyaji, R | 1 |
| Anan, T | 1 |
| Yabe, M | 1 |
| Kamizono, J | 1 |
| Merlotti, D | 1 |
| Gennari, L | 1 |
| Martini, G | 1 |
| Valleggi, F | 1 |
| De Paola, V | 1 |
| Avanzati, A | 1 |
| Nuti, R | 1 |
1 review available for pamidronate and Adverse Drug Event
| Article | Year |
|---|---|
Atrial fibrillation in patients treated with intravenous zoledronic or pamidronic acid: a pharmacoepidemiological study.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Atrial Fibrillation; Databases, Factual; Drug- | 2021 |
1 trial available for pamidronate and Adverse Drug Event
| Article | Year |
|---|---|
Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
Topics: Aged; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Hu | 2007 |
6 other studies available for pamidronate and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
Patient-reported effectiveness and safety of Pamidronate in NSAIDs-refractory chronic recurrent multifocal osteomyelitis in children.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Child; Chronic Disease; Drug-Related Side Effects and Adver | 2022 |
Sarcoglycans and integrins in bisphosphonate treatment: immunohistochemical and scanning electron microscopy study.
Topics: Bone Neoplasms; Bone Resorption; Calcification, Physiologic; Cell Adhesion; Diphosphonates; Drug-Rel | 2013 |
Nationwide survey of bisphosphonate therapy for children with reactivated Langerhans cell histiocytosis in Japan.
Topics: Adolescent; Child; Child, Preschool; Diphosphonates; Disease-Free Survival; Drug Evaluation; Drug-Re | 2011 |